Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Trinity Biotech PLC changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 27 | 25 | −2 |
| Shares | 821.8K | 2.56M | +1.74M (+211.4%) |
| Value | $468.1K | $1.66M | +$1.19M (+255.3%) |
New holders (3)
Institutions that held Trinity Biotech PLC at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Perceptive Advisors LLC | 1,790,000 | $1.16M | 0.04% |
| XTX Topco Ltd | 25,751 | $17.1K | 0.00% |
| CoreCap Advisors, LLC | 1 | $1 | 0.00% |
Sold out (5)
Institutions that held Trinity Biotech PLC at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| HRT Financial LP | 66,242 | $37.0K |
| Citadel Advisors LLC | 41,539 | $23.7K |
| Two Sigma Securities, LLC | 17,547 | $10.0K |
| Morgan Stanley | 2,160 | $1.23K |
| GAMMA Investing LLC | 643 | $367 |